Biallelic mutation of MSH2 in primary human cells is associated with sensitivity to irradiation and altered RAD51 foci kinetics
Open Access
- 16 March 2007
- journal article
- case report
- Published by BMJ in Journal of Medical Genetics
- Vol. 44 (8) , 516-520
- https://doi.org/10.1136/jmg.2006.048660
Abstract
Background: Reports of differential mutagen sensitivity conferred by a defect in the mismatch repair (MMR) pathway are inconsistent in their conclusions. Previous studies have investigated cells established from immortalised human colorectal tumour lines or cells from animal models. Methods: We examined primary human MSH2-deficient neonatal cells, bearing a biallelic truncating mutation in MSH2, for viability and chromosomal damage after exposure to DNA-damaging agents. Results: MSH2-deficient cells exhibit no response to interstrand DNA cross-linking agents but do show reduced viability in response to irradiation. They also show increased chromosome damage and exhibit altered RAD51 foci kinetics after irradiation exposure, indicating defective homologous recombinational repair. Discussion: The cellular features and sensitivity of MSH2-deficient primary human cells are broadly in agreement with observations of primary murine cells lacking the same gene. The data therefore support the view that the murine model recapitulates early features of MMR deficiency in humans, and implies that the variable data reported for MMR-deficient immortalised human cells may be due to further genetic or epigenetic lesions. We suggest caution in the use of radiotherapy for treatment of malignancies in individuals with functional loss of MSH2.Keywords
This publication has 22 references indexed in Scilit:
- The Fanconi Anemia/BRCA pathway: new faces in the crowdGenes & Development, 2005
- Mismatch repair and DNA damage signallingDNA Repair, 2004
- Mismatch repair and response to DNA-damaging antitumour therapiesEuropean Journal Of Cancer, 2003
- GeneNote: whole genome expression profiles in normal human tissuesComptes Rendus Biologies, 2003
- The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phaseOncogene, 2003
- Early-Onset Brain Tumor and Lymphoma in MSH2-Deficient ChildrenAmerican Journal of Human Genetics, 2003
- Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors.2002
- A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple café-au-lait spots.2002
- Oligoclonal T Cell Expansions in Pulmonary Lymphoproliferative DisordersAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Mismatch repair, G 2 /M cell cycle arrest and lethality after DNA damageCarcinogenesis: Integrative Cancer Research, 1999